Press Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Jan 9, 2018Dr. Ascher Shmulewitz, Interim CEO, Discusses Strategy That Includes Additions to Drug Development
Therapix Biosciences Ltd. (NASDAQ: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, is expanding...
-
Dec 4, 2017- Top-Line Results Currently Anticipated in Early 2018 -
Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based therapies, announces the completion of enrollment...
-
Nov 21, 2017
Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, has received...
-
Nov 10, 2017Executes Material Transfer Agreement with Yissum for Two Synthetic Agonists Synthesized by Professor Raphael Mechoulam
Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based treatments, executed a non-exclusive material...
-
Nov 9, 2017- Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT -
Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based treatments, today reported financial results for...